American Heart Journal
Volume 154, Issue 2 , Pages 277.e1-277.e8 , August 2007

Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: A report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)

  • Barry H. Greenberg, MD

      Affiliations

    • University of California-San Diego Medical Center, San Diego, CA
    • Corresponding Author InformationReprint requests: Barry H. Greenberg, MD, University of California-San Diego Medical Center, 200 W. Arbor Drive, #8411, San Diego, CA 92103-8411.
    • ,
  • William T. Abraham, MD

      Affiliations

    • Ohio State University, Columbus, OH
    • ,
  • Nancy M. Albert, PhD, RN

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, OH
    • ,
  • Karen Chiswell, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Robert Clare, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Wendy Gattis Stough, PharmD

      Affiliations

    • Duke University Medical Center, Durham, NC
    • ,
  • Mihai Gheorghiade, MD

      Affiliations

    • Northwestern Feinberg School of Medicine, Chicago, IL
    • ,
  • Christopher M. O'Connor, MD

      Affiliations

    • Duke University Medical Center, Durham, NC
    • ,
  • Jie Lena Sun, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Clyde W. Yancy, MD

      Affiliations

    • Baylor University Medical Center, Dallas, TX
    • ,
  • James B. Young, MD

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, OH
    • ,
  • Gregg C. Fonarow, MD

      Affiliations

    • UCLA Medical Center, Los Angeles, CA

Received 30 January 2007 ,Accepted 1 May 2007.

References 

  1. Kannel WB, D'Agostino RB, Silbershatz H, et al. Profile for estimating risk of heart failure. Arch Intern Med. 1999;159:1197–1204
  2. Nichols GA, Hillier TA, Erbey JR, et al. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24:1614–1619
  3. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29–34
  4. MERIT-HF Investigators . Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007
  5. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7–13
  6. CONSENSUS Trial Study Group . Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429–1435
  7. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667–1675
  8. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–1587
  9. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–781
  10. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting–enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–153
  11. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. A meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41:1529–1538
  12. Deedwania PC, Giles TD, Klibaner M, et al. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J. 2005;149:159–167
  13. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines American College of Cardiology Website. Available at: http://www.acc.org/qualityandscience/clinical/guidelines/failure/update/index.pdf2005;
  14. Adams KF, Lindenfeld J, Arnold JMO, et al. HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006;12:e1–e122
  15. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non–insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med. 1997;126:955–959
  16. Jacob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens. 1996;14:489–494
  17. Fonarow GC, Abraham WT, Albert NM, et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J. 2004;148:43–51
  18. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296:2217–2226
  19. Fonarow GC, Abraham WT, Albert NM, et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA. 2007;297:61–70
  20. Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–216
  21. Lee DS, Austin PC, Rouleau JL, et al. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581–2587
  22. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27:65–75
  23. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trials and registry. Am J Cardiol. 1996;77:1017–1020
  24. Gustafsson I, Brendorp B, Seibaek M, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol. 2004;43:771–777
  25. Domanski M, Krause-Steinrauf H, Deedwania P, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003;42:914–922
  26. Dries DL, Sweitzer NK, Drazner MH, et al. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol. 2001;38:421–428

 The OPTIMIZE-HF registry and this study were supported by GlaxoSmithKline, Philadelphia, PA.

 The OPTIMIZE-HF registry is registered: www.clinicaltrials.gov, study number NCT00344513.

PII: S0002-8703(07)00414-0

doi: 10.1016/j.ahj.2007.05.001

American Heart Journal
Volume 154, Issue 2 , Pages 277.e1-277.e8 , August 2007

Article Tools

* Image Usage & Resolution